Tyrosine kinase inhibitors and COVID-19

J Oncol Pharm Pract. 2020 Dec;26(8):2072-2073. doi: 10.1177/1078155220967081. Epub 2020 Oct 21.

Authors

Başcı Semih¹, Yiğenoğlu Tuğçe Nur¹, Dal Mehmet Sinan¹, Korkmaz Serdal², Turgut Burhan³, Altuntaş Fevzi¹

Affiliations

¹ Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
² Department of Hematology, Kayseri City Hospital, University of Health Sciences, Kayseri, Turkey.
³ Department of Hematology, School of Medicine, Namık Kemal University, Tekirdağ, Turkey.

PMID: 33081581
DOI: 10.1177/1078155220967081

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Pandemics
Protein Kinase Inhibitors / adverse effects
SARS-CoV-2

Substances

Protein Kinase Inhibitors